Connect with us

Business

Cyclical Stocks Rise on Vaccine News

Avatar

Published

on

A word Cyclical is a part of Investment&Wealth management in stock photo-Cyclical Stocks Rise-ss-featured

Cyclical stocks rise as Pfizer’s Covid-19 vaccine hogs the headlines. As the S&P 500 posted a small loss and the Nasdaq closed lower, cyclical stocks are among the top gainers in the market. The Dow Jones Industrial Average went up 262.95 points, or 0.9%, to 29,420.92. Meanwhile, the S&P 500 dropped 4.97 points, or 0.14%, to 3,545.53. Tech-heavy Nasdaq Composite fell 159.93 points, or 1.37%, to 11,553.86.

RELATED: Market Loses 500 Points, More Pain Could Be In Store For Investors

The blue-chip Dow and its industrial shares rose as crude oil prices went higher. The Dow outperformed tech-heavy Nasdaq by 6.74 percentage points this week. It is the largest two-day performance spread since March 2001. Its close of 29,420.92 on Tuesday is its third-highest close in history. Among its biggest gainers were 3M, Chevron, and Boeing. 

Covid-19 Vaccine News Led to Tech Sell Offs

Pfizer announced last Monday that its Covid-19 vaccine showed a 90% success rate. The vaccine, developed with German firm BioNTech, plans to apply for emergency authorization. This can happen later this month once they complete safety data collection. 

Investors took this as a sign that a return to normal is nearing. They engaged in profit-taking from tech stocks. These companies profited the most from the pandemic. They increased their net worth by leaps and bounds. The sell-offs pushed Nasdaq, which is tech-heavy, into negative territory. 

Cyclical Stocks Rise Beyond the Virus Horizon

Tim Ghriskey, the chief investment strategist at Inverness Counsel, says the cycle has begun. “Equity markets in the U.S. have experienced the start of a significant rotation following the vaccine announcement. It’s been a dramatic change and it’s all in anticipation of returning to some form of economic normalcy once the vaccine has been distributed to the broad population.”

“The caveat is there’s a second wave to the virus that’s infecting a record number of people,” Ghriskey added. “But at least for now, the markets are willing to look through that economic pain to better days ahead once the virus has been eradicated.”

Oil Surges Ahead, While the Dollar and Gold Ticks Up

On Monday, oil prices extended its surge. Crude recorded its biggest daily percentage gain in five months. The potential solution to the coronavirus proved to be too irresistible to investors. Oil prices gained despite lower demand. Some countries imposed new lockdowns to contain the virus, causing the drop-off. U.S. crude rose 2.66% to settle at $41.36 per barrel, while Brent settled at $43.61 per barrel, up 2.85% on the day.

The dollar held firm as the forex markets absorbed Monday’s vaccine-fueled moves. The dollar index rose 0.08% while the euro fell 0.05% to $1.1807. Gold regained some ground lost, rising 0.6% to $1,873.53 an ounce.

Too Early to Shift

Experts warn that the cyclical stocks rise might be too early. Nick Brooks, head of economic and investment research at Intermediate Capital Group says there’s a lot to do. “The pandemic still has a ways to go, unfortunately,” he said. “Pfizer development is a great development, but I don’t think it’s the game-changer that markets seem to perceive.”

Let’s assume the vaccine gets emergency use approval by November. Production and delivery of the doses, plus actual vaccinations will still take time. Even more important, there is the question of how long the immunity lasts. “It’s far too early for investors to be making a structural shift from growth to value,” Brooks added. “There’s been pretty substantial damage to economies and that’s going to take some time to repair.” He warned that markets might remain volatile for the time being.

What Happens to Stimulus Then?

Investors remain on the lookout for updates to the long-awaited stimulus package. While aid remains a priority, Congress might not see the need for a bigger budget. The positive vaccine development plus an improving economy means less to worry about. 

Esty Dwek, head of global market strategy at Natixis Investment Managers, thinks the urgency already passed. “These more promising vaccine developments are an argument for Republicans to delay or to have a smaller-scale stimulus,” she said. “We will definitely get something, even if it’s smaller deals like airlines and more targeted measures.”

Watch this as Fox59 News presents Strategic wealth advice and explains why a coronavirus vaccine could impact the markets:

As cyclical stocks rise in favor of tech stocks, is it time to sell off tech/growth stocks in favor of value/cyclical?

Please Select One:

View Results

Loading ... Loading ...

Given the developments, are you switching to value (cyclical) stocks over growth stocks now? Do you think tech stock investors will now start to sell off as the danger of coronavirus wanes? Let us know what you think by sharing your thoughts in the comment section below.

Click to comment

Leave a Comment

Subscribe To Our Newsletter:

Advertisement

Facebook

Copyright © 2020 The Capitalist. his copyrighted material may not be republished without express permission. The information presented here is for general educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that this website has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this page and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. This website contains advertisements.

[email]
[email]